Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2 is a dataset published in JCO Precision Oncology (2024). On theSindex it has a DataRank of 0.476, placing it in the top 40.1% of the data-sharing corpus. It has been cited 10 times, with 10 citing works in its 1-hop citation network.
Ranks in the top 40% for downstream scientific impact
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.360
From this paper's citation signal
Citation Network Contribution
0.116
From 8 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 10 citers.
NCI NIH HHS
Grant: U24 CA196172
NCI NIH HHS
Grant: UG1 CA233339
NCI NIH HHS
Grant: U10 CA180820
NCI NIH HHS
Grant: UG1 CA233302
NCI NIH HHS
Grant: U10 CA180794
NCI NIH HHS
Grant: UG1 CA233180
NCI NIH HHS
Grant: UG1 CA233341
FWCI
1.58
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals